108 related articles for article (PubMed ID: 27231555)
1. Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines.
Lopez-Acevedo M; Grace L; Teoh D; Whitaker R; Adams DJ; Jia J; Nixon AB; Secord AA
Gynecol Oncol Res Pract; 2014; 1():2. PubMed ID: 27231555
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.
Secord AA; Teoh D; Jia J; Nixon AB; Grace L; Adams DJ; Murphy SK
Int J Gynecol Cancer; 2014 Feb; 24(2):218-25. PubMed ID: 24407585
[TBL] [Abstract][Full Text] [Related]
3. Gamma Secretase Inhibitors as Potential Therapeutic Targets for Notch Signaling in Uterine Leiomyosarcoma.
Abedin Y; Gabrilovich S; Alpert E; Rego E; Begum S; Zhao Q; Heller D; Einstein MH; Douglas NC
Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682660
[TBL] [Abstract][Full Text] [Related]
4. Src: a potential target for the treatment of triple-negative breast cancer.
Tryfonopoulos D; Walsh S; Collins DM; Flanagan L; Quinn C; Corkery B; McDermott EW; Evoy D; Pierce A; O'Donovan N; Crown J; Duffy MJ
Ann Oncol; 2011 Oct; 22(10):2234-40. PubMed ID: 21357651
[TBL] [Abstract][Full Text] [Related]
5. Carboplatin-paclitaxel- and carboplatin-docetaxel-induced cytotoxic effect in epithelial ovarian carcinoma in vitro.
Engblom P; Rantanen V; Kulmala J; Grènman S
Cancer; 1999 Nov; 86(10):2066-73. PubMed ID: 10570433
[TBL] [Abstract][Full Text] [Related]
6. The effects of the CDK inhibitor seliciclib alone or in combination with cisplatin in human uterine sarcoma cell lines.
Coley HM; Shotton CF; Kokkinos MI; Thomas H
Gynecol Oncol; 2007 May; 105(2):462-9. PubMed ID: 17300833
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.
Lützen U; Zhao Y; Lucht K; Zuhayra M; Marx M; Cascorbi I; Culman J
Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):37-48. PubMed ID: 27664035
[TBL] [Abstract][Full Text] [Related]
8. Functionality of the Tumor Suppressor
Stope MB; Cernat V; Kaul A; Diesing K; Koensgen D; Burchardt M; Mustea A
Anticancer Res; 2018 Mar; 38(3):1547-1550. PubMed ID: 29491084
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibitory effect of the Src inhibitor dasatinib in combination with anticancer agents on uterine cervical adenocarcinoma cells.
Takiguchi E; Nishimura M; Mineda A; Kawakita T; Abe A; Irahara M
Exp Ther Med; 2017 Nov; 14(5):4293-4299. PubMed ID: 29067110
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
12. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
[TBL] [Abstract][Full Text] [Related]
13. Curdione Induces Antiproliferation Effect on Human Uterine Leiomyosarcoma
Wei C; Li D; Liu Y; Wang W; Qiu T
Front Oncol; 2021; 11():637024. PubMed ID: 33718227
[TBL] [Abstract][Full Text] [Related]
14. EP4 and Class III β-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment.
Reader J; Harper AK; Legesse T; Staats PN; Goloubeva O; Rao GG; Fulton A; Roque DM
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635323
[TBL] [Abstract][Full Text] [Related]
15. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma
Kawakita T; Masato N; Takiguchi E; Abe A; Irahara M
Exp Ther Med; 2017 Jun; 13(6):2939-2945. PubMed ID: 28587364
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
El Sayed I; Helmy MW; El-Abhar HS
Life Sci; 2018 Nov; 213():248-257. PubMed ID: 30292831
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.
Vallo S; Michaelis M; Gust KM; Black PC; Rothweiler F; Kvasnicka HM; Blaheta RA; Brandt MP; Wezel F; Haferkamp A; Cinatl J
BMC Res Notes; 2016 Sep; 9(1):454. PubMed ID: 27677700
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial to assess the activity of gemcitabine and docetaxel as first line chemotherapy treatment in patients with unresectable leiomyosarcoma.
Seddon B; Scurr M; Jones RL; Wood Z; Propert-Lewis C; Fisher C; Flanagan A; Sunkersing J; A'Hern R; Whelan J; Judson I
Clin Sarcoma Res; 2015; 5():13. PubMed ID: 25987978
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
